AstraZeneca Withdraws Drug for Hairy Cell Leukemia From US Market AstraZeneca Withdraws Drug for Hairy Cell Leukemia From US Market

The company is planning to remove its leukemia drug moxetumomab pasudotox-tdfk (Lumoxiti) from the US market, saying there has been ' very low clinical uptake ' of the product.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news